Aqtual, Inc.—a trailblazer in precision medicine—has proudly announced a milestone funding round of $31,000,000, a strong endorsement of its innovative approach to healthcare. This significant capital injection will accelerate Aqtual’s mission of revolutionizing treatment strategies for chronic diseases and oncology using its novel cell-free DNA platform. By bridging the translational gap between groundbreaking research and practical healthcare solutions, Aqtual is uniquely positioned to bring about a paradigm shift in how these conditions are diagnosed and managed. The newly raised funds will primarily support the expansion of ongoing research and the development of next-generation diagnostic and therapeutic products, enabling the company to speed up clinical trials and push the boundaries of current medical science. With this strategic investment, the company intends to enhance its precision diagnostic capabilities, optimize its research and development processes, and forge critical partnerships with leading healthcare institutions. Aqtual’s dedication to producing highly accurate, non-invasive tests promises to not merely detect diseases earlier but also to facilitate personalized treatment plans, thereby improving patient outcomes significantly. The infusion of $31 million not only reflects strong investor confidence in Aqtual’s technological approach but also underscores a broader commitment to transforming chronic disease management. As the company scales its operations and integrates state-of-the-art data analytics with its cell-free DNA platform, patients can expect faster, more targeted interventions that mirror the latest advances in medical research. This funding milestone marks an important step forward in the continuous pursuit of clinical excellence and innovation in precision medicine, setting the stage for future breakthroughs in both chronic disease and oncology care.
Aqtual Secures $31M Series B to Revolutionize Precision Medicine for Chronic Diseases and Oncology
Get the full Aqtual company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Mantle8
We are a new generation of geologists leading the energy revolution by locating the Earth’s naturally occurring hydrogen reservoirs. Using bottom-up exploration and decades of geology experience, we are on a mission to deliver natural hydrogen to the world. Check out this short video explainer for more details: https://vimeo.com/1116223132
$36.6M Series a
today
Data Mission
We build purpose-driven tools that help cities and counties work smarter - from RFP creation and cost estimation to budgeting, workforce planning, and community insights. Our platform replaces spreadsheets and manual workflows with intelligent, transparent systems tailored to the complexities of local government. Whether you’re planning capital projects, managing procurement, or forecasting community needs, we give public agencies the clarity and confidence to lead with data.
$1.0M Seed
today
SiteVue AI
Empowering the frontline worker with AI to drive automated continuous improvement while improving safety and employee engagement.
$7.0M Seed
today
Peekabox
Peekabox is a food-tech platform helping bakeries, restaurants, and grocery stores across the GCC sell their surplus food at 50-70% off. Every day, thousands of freshly prepared food items are thrown away across the region. In the UAE alone, over $3.5 billion worth of food is wasted annually, 38% of everything prepared daily ends up in the bin. That's a massive problem for retailers, consumers, and the planet. We partner with leading F&B brands and retailers to list their unsold surplus as surprise boxes on our platform. Customers reserve and collect them in-store at guaranteed minimum discounts of 50%. Retailers turn waste into revenue. Consumers get quality food at a fraction of the price. Everybody wins. 1,000+ stores signed across 50+ brands including Costa, Carrefour, Tim Hortons, Dunkin', Paul, Armani Cafe, Eataly, Pret A Manger, Krispy Kreme, Address Hotels, and many more. Backed by some of the most prominent business leaders in the region, chaired by Dr Sameer Al Ansari, Former CFO of H.H Sheikh Mohammed's Executive Office and former CEO Dubai International Capital. For consumers → Download Peekabox and start saving on food from your favourite stores. For partners → List your surplus in 15 seconds and turn food waste into revenue. Get in touch → hello@peekabox.co
$1.5M Pre-seed
today
Aumet inc
Aumet is dedicated to providing tailored solutions that enhances the performance of healthcare providers, operating in Saudi Arabia, Jordan, Egypt and Oman It is a Saudi company that was Originally established in the United States, Aumet is now the largest B2B healthcare solution provider that supports companies with their business decisions and performance. Aumet facilitates the exchange of data between healthcare providers, manufacturers, and distributors to enable them to take the right decision.
$12.0M Series a
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  NVISION Spain | Series b | $55.0M | today |
| 2 |  Monaco | Series b | $50.0M | today |
| 3 |  gaiia | Series b | $40.0M | today |
| 4 |  ZAMP Brazil | Series b | $17.0M | today |
| 5 |  Cinder | Series b | $41.0M | today |